admin – Page 6900 – Get News Story

EGFR-Non Small Cell Lung Cancer Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Abbvie, Novartis, Daiichi Sankyo

“EGFR-Non Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the EGFR-Non Small Cell Lung Cancer, historical and forecasted epidemiology as well as the EGFR-Non Small Cell Lung Cancer market trends in the 7MM.

DelveInsight’s “EGFR-Non Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the EGFR-Non Small Cell Lung Cancer, historical and forecasted epidemiology as well as the EGFR-Non Small Cell Lung Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the EGFR-Non Small Cell Lung Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; EGFR-Non Small Cell Lung Cancer Market Forecast

Some of the key facts of the EGFR-Non Small Cell Lung Cancer Market Report:

The EGFR-Non Small Cell Lung Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In October 2023, Janssen, a subsidiary of Johnson & Johnson based in Belgium, has released results from the Phase III MARIPOSA-2 clinical study of Rybrevant (amivantamab-vmjw) regimens in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). This randomized trial, conducted in an open-label fashion, evaluated the safety and effectiveness of two different treatment protocols involving Rybrevant in combination with chemotherapy, with and without lazertinib.
In September 2023, The Janssen Pharmaceutical Companies, a division of Johnson & Johnson, have released positive initial findings from the Phase 3 MARIPOSA trial assessing RYBREVANT® (amivantamab-vmjw), a bispecific antibody targeting the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), when used alongside lazertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI), compared to osimertinib as the first-line therapy for patients diagnosed with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).
Among the European 5 countries, Germany had the highest cases of NSCLC. Furthermore, Japan accounts for about 117,752 cases in 2020
DelveInsight’s analysts have estimated that in 2020, in the United States there were over 38,000 incident cases for EGFR mutation.
The highest number of Non Small Cell Lung Cancer were estimated in the United States
Key EGFR-Non Small Cell Lung Cancer Companies: Abbvie, Yuhan Corporation, Janssen Research & Development), Novartis, Daiichi Sankyo, and others
Key EGFR-Non Small Cell Lung Cancer Therapies: Telisotuzumab Vedotin(Teliso-V), Lazertinib (Leclaza), Nazartinib (EGF816), Patritumab deruxtecan (HER3-DXd), and others
The EGFR-NSCLC epidemiology based on gender analyzed that in the United States, 7 out of 10 patients had metastatic NSCLC (Stage III b and IV)
The EGFR-Non Small Cell Lung Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage EGFR-Non Small Cell Lung Cancer pipeline products will significantly revolutionize the EGFR-Non Small Cell Lung Cancer market dynamics.

EGFR-Non Small Cell Lung Cancer Overview

There are mainly two types of lung cancer small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adeno squamous carcinomas, and sarcomatoid carcinomas.

Get a Free sample for the EGFR-Non Small Cell Lung Cancer Market Report –

https://www.delveinsight.com/sample-request/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market

EGFR-Non Small Cell Lung Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

EGFR-Non Small Cell Lung Cancer Epidemiology Segmentation:

The EGFR-Non Small Cell Lung Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of EGFR-Non Small Cell Lung Cancer
Prevalent Cases of EGFR-Non Small Cell Lung Cancer by severity
Gender-specific Prevalence of EGFR-Non Small Cell Lung Cancer
Diagnosed Cases of Episodic and Chronic EGFR-Non Small Cell Lung Cancer

Download the report to understand which factors are driving EGFR-Non Small Cell Lung Cancer epidemiology trends @ EGFR-Non Small Cell Lung Cancer Epidemiology Forecast

EGFR-Non Small Cell Lung Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the EGFR-Non Small Cell Lung Cancer market or expected to get launched during the study period. The analysis covers EGFR-Non Small Cell Lung Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the EGFR-Non Small Cell Lung Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

EGFR-Non Small Cell Lung Cancer Therapies and Key Companies

Telisotuzumab Vedotin(Teliso-V): Abbvie
Lazertinib (Leclaza): Yuhan Corporation/ Janssen Research & Development)
Nazartinib (EGF816): Novartis
Patritumab deruxtecan (HER3-DXd): Daiichi Sankyo

Discover more about therapies set to grab major EGFR-Non Small Cell Lung Cancer market share @ EGFR-Non Small Cell Lung Cancer Treatment Market

EGFR-Non Small Cell Lung Cancer Market Drivers

Increasing Use of Biomarker Testing
Increase in the Mutation Specific Trials Activity and Approval
Increasing Incidence of NSCLC
Rich Pipeline and label expansion of approved therapies

EGFR-Non Small Cell Lung Cancer Market Barriers

Cost-Effectiveness of Therapies
Small Patient Populations for Specific Subsets of NSCLC
Generic or Biosimilar Erosion

Scope of the EGFR-Non Small Cell Lung Cancer Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key EGFR-Non Small Cell Lung Cancer Companies: Abbvie, Yuhan Corporation, Janssen Research & Development), Novartis, Daiichi Sankyo, and others
Key EGFR-Non Small Cell Lung Cancer Therapies: Telisotuzumab Vedotin(Teliso-V), Lazertinib (Leclaza), Nazartinib (EGF816), Patritumab deruxtecan (HER3-DXd), and others
EGFR-Non Small Cell Lung Cancer Therapeutic Assessment: EGFR-Non Small Cell Lung Cancer current marketed and EGFR-Non Small Cell Lung Cancer emerging therapies
EGFR-Non Small Cell Lung Cancer Market Dynamics: EGFR-Non Small Cell Lung Cancer market drivers and EGFR-Non Small Cell Lung Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
EGFR-Non Small Cell Lung Cancer Unmet Needs, KOL’s views, Analyst’s views, EGFR-Non Small Cell Lung Cancer Market Access and Reimbursement

To know more about EGFR-Non Small Cell Lung Cancer companies working in the treatment market, visit @ EGFR-NSCLC Clinical Trials and Therapeutic Assessment

Table of Contents

1. EGFR-Non Small Cell Lung Cancer Market Report Introduction

2. Executive Summary for EGFR-Non Small Cell Lung Cancer

3. SWOT analysis of EGFR-Non Small Cell Lung Cancer

4. EGFR-Non Small Cell Lung Cancer Patient Share (%) Overview at a Glance

5. EGFR-Non Small Cell Lung Cancer Market Overview at a Glance

6. EGFR-Non Small Cell Lung Cancer Disease Background and Overview

7. EGFR-Non Small Cell Lung Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of EGFR-Non Small Cell Lung Cancer

9. EGFR-Non Small Cell Lung Cancer Current Treatment and Medical Practices

10. EGFR-Non Small Cell Lung Cancer Unmet Needs

11. EGFR-Non Small Cell Lung Cancer Emerging Therapies

12. EGFR-Non Small Cell Lung Cancer Market Outlook

13. Country-Wise EGFR-Non Small Cell Lung Cancer Market Analysis (2019–2032)

14. EGFR-Non Small Cell Lung Cancer Market Access and Reimbursement of Therapies

15. EGFR-Non Small Cell Lung Cancer Market Drivers

16. EGFR-Non Small Cell Lung Cancer Market Barriers

17. EGFR-Non Small Cell Lung Cancer Appendix

18. EGFR-Non Small Cell Lung Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: EGFR-Non Small Cell Lung Cancer Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Abbvie, Novartis, Daiichi Sankyo

A Rousing Revival of Classic American Rock With a Modern Twist – Kenny Dubman Unleashes “Kentucky Breeze”

Kenny Dubman captures the essence of 70s Rock and Americana, offering listeners a heartfelt, guitar-Driven journey through Americana music

With the launch of “Kentucky Breeze” on March 12, 2024, Kenny Dubman does not just release an album, but rather, reignites the embers of classic rock with a fervor that is both nostalgic and refreshingly new.

Recorded amidst the golden hues of fall 2023 at Sound Spa Studios, Edison, New Jersey, this masterpiece is the culmination of Dubman’s lifelong journey through the heart of rock music. Stephen Deacutis, wielding the engineering baton, alongside Jersey’s own Joe Bellia (drums), Rob Clores (keys), and Eric Winnicki (bass), has helped forge a sound that is as compelling as it is authentic.

“Kentucky Breeze” is an album which ncapsulates the dual essence of Kenny Dubman’s artistic vision: the unbridled energy of 70s rock blended seamlessly with the soul-stirring depth of Americana. It’s an album that speaks to the core of the human experience, offering narratives that resonate with anyone who’s ever dared to dream, to feel, and to seek the truth.

From the electrifying riffs that demand your attention to the introspective acoustic melodies that invite contemplation, Dubman masterfully balances the spectrum of human emotion, crafting songs that linger long after the last note fades.

In the pursuit of his musical odyssey, Dubman is unequivocal about his aspirations: to connect with fans worldwide and to embark on a never-ending tour that celebrates the communal spirit of rock ‘n’ roll. “Kentucky Breeze” presents audiences with a pathway to rediscovery, a bridge between eras, and a beacon of hope for the future of American music!

In a world where music often becomes a fleeting echo, Kenny Dubman’s “Kentucky Breeze” stands as a monument to the enduring power of Rock. It forms a strong reminder of the beauty that arises from authenticity, the strength born of vulnerability, and the unbreakable connection between an artist and their audience.

Stream the new release on Spotify and follow the artist on Instagram (@officialkennydubman), and YouTube (@kennydubman1395) to keep track of new and upcoming music! The artist extends an invitation to listeners everywhere to join him on this journey – a call to experience the raw, unfiltered essence of music, to share in the stories that bind us, and to keep the flame of rock ‘n’ roll burning bright.

ABOUT

Embarking on a sonic voyage that transcends time, Kenny Dubman emerges as the quintessential rocker with his groundbreaking album, “Kentucky Breeze.” Dubman, a figure synonymous with the gritty essence of American rock, has crafted a legacy that mirrors the very evolution of the genre. From the smoke-filled clubs of New Jersey to the hallowed halls of major label success with Prophet, and now, to a deeply personal return to his musical roots, Dubman’s career is a testament to resilience, passion, and an undying love for rock ‘n’ roll. With his latest work, Dubman invites listeners to partake in an audacious exploration of life’s intricate tapestry, underscored by the raw power of guitar and the honesty of Americana music.

LINKS

Facebook: https://www.facebook.com/kennydubman

Instagram: https://www.instagram.com/officialkennydubman/

YouTube: https://www.youtube.com/channel/UCnRvb1y_CM9gnx08mOurt6A

Spotify: https://open.spotify.com/artist/4HjDCoXGGAi5HwMMbgVYLp

Media Contact
Contact Person: Kenny Dubman
Email: Send Email
Phone: 800-983-1362
City: Tinton Falls
State: New Jersy
Country: United States
Website: https://www.facebook.com/kennydubman

Queens World Film Festival Offers Unparalleled Access to Filmmakers

13th Annual Event Provides Unique Opportunities for Audience Engagement

Queens, NY – April 10, 2024 – The Queens World Film Festival (QWFF) is not only known for its exceptional lineup of films but also for its commitment to fostering meaningful connections between filmmakers and their audiences. As the 13th annual event approaches, running from April 16-28, 2024, the festival organizers are excited to announce a variety of opportunities for attendees to engage with the creative minds behind the films.

Because the festival is curated thematically by grouping like minded films together around central themes, each bloc is lovingly assembled to provide a provocative unique cinematic experience. The Opening night film bloc is called Take This: 7 films that won’t back down, followed by 13 days where the festival serves up an eclectic menu of Documentaries, Narratives, Web Series, Dance Films and Experimental FIlms.

One of the festival’s signature events is the Welcoming Night, held on April 16th at Sac’s Place in Astoria. This live broadcast event, hosted by the QWFF Board of Directors, features an interactive Zoom session with filmmakers from around the world who are unable to attend the festival in person. Attendees will have the chance to ask questions, learn about the inspiration behind the films, and gain insight into the creative process.

Throughout the festival, Q&A sessions will be held after all screenings, providing a platform for filmmakers to discuss their work and engage with the audience directly. These intimate gatherings allow for a deeper understanding of the films and the opportunity to explore the themes and ideas presented on screen.

“We believe that the magic of cinema lies not only in the stories being told but also in the connections formed between filmmakers and their audiences,” said Katha Cato, Executive Director of QWFF. “With opportunities for engagement, we aim to create a more immersive and enriching experience for everyone involved.”

To further support emerging talent, the festival offers the Passion in Action and Young Filmmakers mentoring programs, which have provided over 400 young people with hands-on experience in production, marketing, outreach, and arts management. By nurturing the next generation of filmmakers, QWFF ensures that diverse voices and stories will continue to be heard.

With an impressive lineup of 152 films from 19 nations, the 13th Annual Queens World Film Festival promises to be an unforgettable experience. More information at queensworldfilmfestival.org – tickets are available on Eventbrite.com. Don’t miss this chance to be a part of this extraordinary celebration of storytelling and community.

Contact:

Katha Cato

Executive Director, Queens World Film Festival

kathacato@gmail.com

Media Contact
Company Name: Queen’s World Film Festival
Contact Person: Katha Cato Executive Director
Email: Send Email
Country: United States
Website: https://queensworldfilmfestival.org/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Queens World Film Festival Offers Unparalleled Access to Filmmakers

Metastatic Breast Cancer Pipeline Assessment: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | RemeGen, SynCore Biotech, Allarity Therapeutic

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Metastatic Breast Cancer pipeline constitutes 100+ key companies continuously working towards developing 100+ Metastatic Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Metastatic Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Metastatic Breast Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Breast Cancer Market.

Some of the key takeaways from the Metastatic Breast Cancer Pipeline Report:

Companies across the globe are diligently working toward developing novel Metastatic Breast Cancer treatment therapies with a considerable amount of success over the years.
Metastatic Breast Cancer companies working in the treatment market are RemeGen, SynCore Biotechnology, Byondis B.V., Sichuan Baili Pharmaceutical, Allarity Therapeutics, Jiangsu Hansoh Pharmaceutical, Kind Pharmaceuticals LLC, Shanghai Miracogen, Dantari, Inc., Phoenix Molecular Designs, Daiichi Sankyo, Rhizen Pharmaceuticals SA, Olema Oncology, Immutep S.A.S, Jiangsu HengRui Medicine, Genor Biopharma, and others, are developing therapies for the Metastatic Breast Cancer treatment

Emerging Metastatic Breast Cancer therapies in the different phases of clinical trials are- Disitamab Vedotin, EndoTAG®-1 (SB05), trastuzumab duocarmazine, GNC 035, Stenoparib (2X-121), HS-10342, AND019, MRG002, DAN-222, PMD-026, Patritumab Deruxtecan, Tenalisib, OP-1250, Eftilagimod alpha, SHR-A1811, GB491+ Fulvestrant, and others are expected to have a significant impact on the Metastatic Breast Cancer market in the coming years.
In October 2023, The first patient was administered medication in a Phase II clinical trial by Carrick Therapeutics, which involves the combination of samuraciclib (CT7001) and Menarini Group’s elacestrant. This trial targets individuals with CDK4/6i resistant HR+/HER2- metastatic breast cancer. Samuraciclib, an oral inhibitor of CDK7 and the first of its kind, is being paired with elacestrant, an oral selective estrogen receptor degrader (SERD).
On May 04, 2022, Rhizen Pharmaceuticals AG revealed positive interim findings from an ongoing Phase 2 trial assessing Tenalisib in individuals with locally advanced or metastatic breast cancer during the ESMO Breast Cancer Meeting in Berlin, Germany from May 3-5, 2022. The data showcased that Tenalisib demonstrated favorable tolerability and promising initial effectiveness when used as a standalone treatment in both primary and secondary resistant metastatic breast cancer (mBC). These encouraging results provide substantial support for the continued advancement of Tenalisib as a prospective treatment option for patients diagnosed with HR+ and HER2- MBC.
In April 2022, Alphamab Oncology made an announcement regarding the presentation of data from the phase II clinical trial featuring the chemo-free treatment regimen involving KN026 alongside KN046 (KN026-203) at the AACR Annual Meeting 2022 (AACR 2022) via an E-poster. Up until August 10, 2021, a total of 24 patients diagnosed with HER2-positive solid tumors other than breast or gastric cancer, who had previously received at least one line of systemic therapy, were enrolled. Among these patients, 20 were eligible for overall response assessment. The results indicated an overall response rate (ORR) of 55.0%, a disease control rate (DCR) of 85.0%, and a 6-month progression-free survival (PFS) rate of 84.1%. Furthermore, among the 11 colorectal cancer (CRC) patients evaluated, the ORR stood at 45.5%, while the DCR was notably higher at 90.9%.
In April 2022, Quantum Leap Healthcare Collaborative™ (Quantum Leap) and Ambrx Biopharma Inc. disclosed their decision to include Ambrx’s antibody-drug conjugate (ADC) ARX788 as a fresh investigational treatment arm in the I-SPY 2.2 TRIAL intended for managing HER2-positive breast cancer in the neoadjuvant setting. Spearheaded by Quantum Leap, the I-SPY 2.2 TRIAL extends the objectives of the I-SPY 2 TRIAL by customizing treatments for individual patients to enhance clinical outcomes.
In March 2022, The Georgetown University researchers that submitted the poster abstract, “SM-88, D/L-alpha-metyrosine, is a novel anti-cancer agent in estrogen receptor-positive breast cancer,” have made it available, according to TYME Technologies, Inc. The abstract was given at the 2022 Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans, Louisiana. The Phase II OASIS trial, which is being conducted by Georgetown University (NCT04720664) at several MedStar Health hospitals, is for patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2 negative (“HR+/HER2-“) breast cancer who have previously received a CDK4/6 inhibitor regimen. TYME Technologies, Inc. announced in September 2021 that the first patient had been dosed in this trial. Georgetown’s academic clinical partner is MedStar Health.
In February 2022, In their Phase 1b monotherapy clinical trial, Phoenix Molecular Designs (PhoenixMD) has stated that patient recruitment and PMD-026 dosing are now complete. PhoenixMD has made significant progress toward moving PMD-026 into Phase 2 combo trials for triple-negative breast cancer (TNBC) and hormone-positive breast cancer with the successful completion of patient enrollment in this Phase 1/1b trial.

Metastatic Breast Cancer Overview

Metastatic breast cancer, also known as stage IV breast cancer, is a form of breast cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body. In metastatic breast cancer, cancer cells break away from the primary tumor in the breast and travel through the bloodstream or lymphatic system to form new tumors (metastases) in distant organs such as the bones, lungs, liver, or brain.

Get a Free Sample PDF Report to know more about Metastatic Breast Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/metastatic-breast-cancer-pipeline-insight

Emerging Metastatic Breast Cancer Drugs Under Different Phases of Clinical Development Include:

Disitamab Vedotin: RemeGen
EndoTAG®-1 (SB05): SynCore Biotechnology
trastuzumab duocarmazine: Byondis B.V.
GNC 035: Sichuan Baili Pharmaceutical Co., Ltd
Stenoparib (2X-121): Allarity Therapeutics
HS-10342: Jiangsu Hansoh Pharmaceutical Co., Ltd.
AND019: Kind Pharmaceuticals LLC
MRG002: Shanghai Miracogen Inc
DAN-222: Dantari, Inc.
PMD-026: Phoenix Molecular Designs
Patritumab Deruxtecan: Daiichi Sankyo Co., Ltd.
Tenalisib: Rhizen Pharmaceuticals SA
OP-1250: Olema Oncology
Eftilagimod alpha: Immutep S.A.S
SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
GB491+ Fulvestrant : Genor Biopharma Co., Ltd

Metastatic Breast Cancer Route of Administration

Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Molecule Type

Metastatic Breast Cancer Molecule Type

Metastatic Breast Cancer Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Metastatic Breast Cancer Pipeline Therapeutics Assessment

Metastatic Breast Cancer Assessment by Product Type
Metastatic Breast Cancer By Stage and Product Type
Metastatic Breast Cancer Assessment by Route of Administration
Metastatic Breast Cancer By Stage and Route of Administration
Metastatic Breast Cancer Assessment by Molecule Type
Metastatic Breast Cancer by Stage and Molecule Type

DelveInsight’s Metastatic Breast Cancer Report covers around 100+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Metastatic Breast Cancer product details are provided in the report. Download the Metastatic Breast Cancer pipeline report to learn more about the emerging Metastatic Breast Cancer therapies

Some of the key companies in the Metastatic Breast Cancer Therapeutics Market include:

Key companies developing therapies for Metastatic Breast Cancer are – RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, and others.

Metastatic Breast Cancer Pipeline Analysis:

The Metastatic Breast Cancer pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Breast Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Breast Cancer Treatment.
Metastatic Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Metastatic Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Metastatic Breast Cancer drugs and therapies

Metastatic Breast Cancer Pipeline Market Drivers

Increasing prevalence of breast cancer, launch of several diagnostic and screening programs are some of the important factors that are fueling the Metastatic Breast Cancer Market.

Metastatic Breast Cancer Pipeline Market Barriers

However, high cost associated with the treatment, several side effects associated with the use of breast cancer therapeutics and other factors are creating obstacles in the Metastatic Breast Cancer Market growth.

Scope of Metastatic Breast Cancer Pipeline Drug Insight

Coverage: Global
Key Metastatic Breast Cancer Companies: RemeGen, SynCore Biotechnology, Byondis B.V., Sichuan Baili Pharmaceutical, Allarity Therapeutics, Jiangsu Hansoh Pharmaceutical, Kind Pharmaceuticals LLC, Shanghai Miracogen, Dantari, Inc., Phoenix Molecular Designs, Daiichi Sankyo, Rhizen Pharmaceuticals SA, Olema Oncology, Immutep S.A.S, Jiangsu HengRui Medicine, Genor Biopharma, and others
Key Metastatic Breast Cancer Therapies: Disitamab Vedotin, EndoTAG®-1 (SB05), trastuzumab duocarmazine, GNC 035, Stenoparib (2X-121), HS-10342, AND019, MRG002, DAN-222, PMD-026, Patritumab Deruxtecan, Tenalisib, OP-1250, Eftilagimod alpha, SHR-A1811, GB491+ Fulvestrant, and others
Metastatic Breast Cancer Therapeutic Assessment: Metastatic Breast Cancer current marketed and Metastatic Breast Cancer emerging therapies
Metastatic Breast Cancer Market Dynamics: Metastatic Breast Cancer market drivers and Metastatic Breast Cancer market barriers

Request for Sample PDF Report for Metastatic Breast Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Metastatic Breast Cancer Report Introduction

2. Metastatic Breast Cancer Executive Summary

3. Metastatic Breast Cancer Overview

4. Metastatic Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5. Metastatic Breast Cancer Pipeline Therapeutics

6. Metastatic Breast Cancer Late Stage Products (Phase II/III)

7. Metastatic Breast Cancer Mid Stage Products (Phase II)

8. Metastatic Breast Cancer Early Stage Products (Phase I)

9. Metastatic Breast Cancer Preclinical Stage Products

10. Metastatic Breast Cancer Therapeutics Assessment

11. Metastatic Breast Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Metastatic Breast Cancer Key Companies

14. Metastatic Breast Cancer Key Products

15. Metastatic Breast Cancer Unmet Needs

16 . Metastatic Breast Cancer Market Drivers and Barriers

17. Metastatic Breast Cancer Future Perspectives and Conclusion

18. Metastatic Breast Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Breast Cancer Pipeline Assessment: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | RemeGen, SynCore Biotech, Allarity Therapeutic

Kuntai Machinery Unveils Top-Grade Lamination, Die Cutting, and Bronzing Machines, Ushering Enhanced Quality and Efficiency in Manufacturing

Kuntai Machinery introduces state-of-the-art lamination, die cutting, bronzing used textile machines, and other industrial equipment to make the production process smoother and more efficient.

Lamination machines die cutting machines, bronzing machines and other machines of higher quality have been presented by Kuntai Machinery. They constantly strive to improve their machines and provide the best machines to their clients. Their commitment to innovation, quality and customer satisfaction has made them a trusted name in the industry. With a strong team of experts and state-of-the-art technology, this factory is poised to continue leading the way in the global market for Lamination machines, die cutting machines, bronzing machines and other machines. All their machines are backed by a comprehensive warranty and after-sales support, ensuring that their clients have a seamless experience with their machines. So whether one is looking for a Textile laminating machine, double belt presses, or a UD fabric crossply machine, Kuntai Machinery has got them covered. Customers can invest in one of their machines today and see the difference it can make in their business.

Kuntai Machinery

The Textile laminating machine is just one of the many innovative products released by Kuntai Machinery. This machine is designed for laminating various types of fabrics, such as cotton, polyester, and nylon. It provides a strong adhesive bond between the layers of fabric, making them more durable and long-lasting. This machine is suitable for use in industries such as textile manufacturing, clothing production, and home furnishing. It is also easy to operate and maintain, making it a popular choice among businesses of all sizes. With the Textile laminating machine, this firm is helping companies streamline their production processes and create high-quality products for their customers.

The double belt presses supplied by Kuntai Machinery are also highly sought after. These machines are ideal for laminating large surface areas of materials, such as leather, foam, and paper. They provide a consistent and uniform pressure throughout the entire lamination process, ensuring high-quality results every time. The double belt presses can also be customized to meet specific production requirements, making them a versatile solution for a variety of industries. With its efficient and precise operation, this machine has become an essential tool for many businesses looking to improve their production process.

Apart from these machines, Kuntai Machinery also provides UD fabric crossply machine, which is used to laminate and bond unidirectional fabrics. This machine is commonly used in industries like aerospace, automotive, and sports equipment manufacturing. It provides a strong and durable bond between layers of fabric, making it perfect for creating composite materials that require strength and stability. With the UD fabric crossply machine, businesses can produce lightweight yet sturdy products that meet industry standards.

About Kuntai Machinery

Kuntai Machinery is a leading global supplier in the lamination, die cutting, and bronzing machine industry. With a commitment to innovation and customer satisfaction, they continue to develop high-quality machines that meet the evolving needs of businesses worldwide. From large scale production facilities to small businesses, it has a wide range of machines suitable for all types of industries. With their comprehensive warranty and after-sales support, customers can trust in the quality and reliability of their products.

Media Contact
Company Name: Kuntai Machinery
Contact Person: Job Lu
Email: Send Email
Phone: +86 18261228899
Country: China
Website: http://www.kuntai-group.com

Blue Digital Media: Revolutionizing Brand Building with Strategic Educational Content

“Empowering brands through education, Blue Digital Media merges strategic video content with transformative learning to build trust and visibility in the digital age.”

Blue Digital Media integrates educational video content with brand promotion, enhancing trust and visibility for professionals and businesses. Video marketing is crucial for brand strategy and shows high ROI, with growing consumer engagement. Blue Digital helps boost brand loyalty through strategic content development. Their strategy aligns educational goals with marketing, creating impactful content that fosters meaningful brand-consumer connections.

In the fast-evolving digital marketplace, the power of video in education and brand building cannot be understated. Blue Digital Media is at the forefront of this innovation, offering transformative solutions that integrate educational content with brand promotion, thereby enhancing both trust and visibility for businesses across various sectors.

Educational video content is more crucial than ever in a brand’s marketing strategy. According to a 2023 HubSpot report, 90% of marketers using video content plan to increase or maintain their spending budget due to high returns on investment. Additionally, video content consumption has soared, with HubSpot noting that 66% of consumers frequently watch video content to learn about brands. This trend is bolstered by findings from Wyzowl, where 92% of marketers reported a positive ROI on video content, up from 87% the previous year.

Blue Digital Media leverages these trends by integrating brands into specially curated digital courses, thus providing an authentic learning experience that resonates with the target audience. This approach not only enriches the consumer’s learning journey but also significantly boosts brand recognition and loyalty. The courses are strategically distributed across a robust network of online learning platforms and supported by wide-reaching press releases published by reputable news outlets, ensuring optimal exposure.

The effectiveness of such educational videos is evident as they serve as a crucial touchpoint for consumers on their purchase journey. With video marketing expected to surge by the end of 2024, Blue Digital’s focused content strategy positions brands directly in view of an engaged, receptive audience. Their services are particularly vital in an era where consumers spend an average of 100 minutes per day watching online videos.

Blue Digital Media’s approach is designed to meet the growing demand for video content that not only educates but engages and inspires. By featuring brands within relevant digital courses, Blue Digital Media not only enhances the learning experience but also builds a lasting connection between the brand and its audience.

As brands continually seek innovative ways to connect with their audiences, Blue Digital Media’s unique model offers a compelling solution that aligns educational goals with strategic marketing objectives. This approach is not just about visibility—it’s about creating meaningful interactions that foster trust and credibility.

For brands looking to build a reputation as thought leaders while significantly enhancing their market reach, partnering with Blue Digital Media offers a gateway to achieving these goals through dynamic and impactful educational content.

Media Contact
Company Name: Blue Digital Media
Contact Person: Public Relations
Email: Send Email
Country: Canada
Website: https://bluedigital.media

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Blue Digital Media: Revolutionizing Brand Building with Strategic Educational Content

Real Estate Selling Agent in San Antonio, TX, Provides Expertise on New Technology Trends in Homebuying

David Beere, an experienced real estate selling agent in San Antonio, TX, is embracing new technology trends to revolutionize the homebuying process. With a deep understanding of the market’s current trajectory, Beere is leading the charge in utilizing cutting-edge tools to enhance the client experience.

“The real estate landscape is transforming rapidly with the advent of new technologies,” says Beere. “As a real estate agent in San Antonio, TX, I’m leveraging these advancements to offer clients an efficient, seamless, and engaging homebuying journey.” From virtual reality tours to smart home features, Beere ensures his listings are at the forefront of the digital revolution.

Beere’s expertise is particularly beneficial for buyers who are navigating the market’s transition amid rising interest rates. As the leading Realtor in San Antonio, TX, he provides strategic guidance to help clients find homes that not only meet their financial constraints but also their desire for modern amenities.

The San Antonio market is seeing a surge in demand for homes that support the evolving lifestyles of buyers, especially those working remotely. Beere is responsive to these needs, showcasing properties with dedicated workspaces and adaptable living areas. “Today’s buyers want homes that can adapt to their changing needs,” Beere observes. “I’m here to help them find exactly that.”

For sellers, Beere’s approach as a Real estate selling agent in San Antonio, TX, includes a focus on marketing homes effectively, using the latest technology to attract discerning buyers. His commitment to innovation and client service has established him as a top choice for those looking to sell their homes in San Antonio.

David Beere is one of the leading Realtors in San Antonio, Texas. His approach to each client means satisfaction each and every time. For those seeking a knowledgeable and experienced Realtor, David Beere’s innovative approach and commitment to client satisfaction make him an ideal choice. Learn more at the website – visit http://www.davidbeere.co/.

Media Contact
Company Name: David Beere, Texas Premier Realty | Real Estate Agent in San Antonio TX
Contact Person: David Beere
Email: Send Email
Phone: +1 210-889-3283
Address:8620 N New Braunfels Ave # 601
City: San Antonio
State: Texas 78217
Country: United States
Website: http://www.davidbeere.co/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Real Estate Selling Agent in San Antonio, TX, Provides Expertise on New Technology Trends in Homebuying

Hiru Corp. (OTC: HIRU): Forging a Path in Metal Mining Exploration

The mining industry, a vital engine of global economic growth, drives innovation, infrastructure development, and wealth generation worldwide. In this dynamic landscape, Hiru Corp. (OTC: HIRU) presents itself as a potential opportunity for investors looking to explore the diverse and potentially lucrative realm of mineral extraction.

Recent Developments:

In a recent development, Hiru Corp. (OTC: HIRU) has proudly introduced Mr. R. Molebatsi (Thebi) as the latest addition to its executive team, serving as the Chief Operating Officer (COO) of its mining division. The appointment of Mr. Thebi underscores the company’s commitment to enhancing its leadership and expertise within the mining sector.

Bringing with him a wealth of experience spanning various industries, including mining, construction, marketing, and customer service, Mr. Thebi is positioned to play a pivotal role in driving forward the company’s vision. His extensive background and proven track record of success make him an invaluable asset to Hiru Corp.’s growth trajectory.

Based in Johannesburg, South Africa, Mr. Thebi’s dedication to social justice and community development is widely recognized. He has been actively involved in spearheading initiatives aimed at creating sustainable employment and economic opportunities for marginalized communities across Africa. His commitment to making a positive impact aligns seamlessly with Hiru Corp.’s values and vision for responsible corporate stewardship.

In his new capacity as COO of the mining division, Mr. Thebi will lead initiatives aimed at expanding the company’s presence in Africa and advancing its gold trading and processing operations in Dubai. The launch of the mining division’s website further underscores HIRU’s commitment to transparency and engagement with stakeholders.

“We are thrilled to welcome Thebi to our team,” said a spokesperson for Hiru Corp. “His extensive experience and dedication to social justice will undoubtedly contribute to our company’s growth and commitment to making a meaningful difference in the communities we serve.”

Additionally, the company has announced plans to sell its water packing equipment, including Alkaline 88, as part of its broader strategy to optimize resources and focus on core business operations.

As HIRU continues to forge ahead in the mining industry, investors can expect further updates on its projects and initiatives, reflecting the company’s dedication to keeping investors informed and driving sustainable growth.

Global Mining Ventures:

Hiru Corp.’s (OTC: HIRU) mining division boasts a diverse and ally positioned portfolio of projects spanning continents. From ventures in Africa aimed at empowering local communities to operations in Dubai tapping into the lucrative gold trading and processing market, the company demonstrates remarkable agility and adaptability in navigating international markets. Furthermore, the critical support provided by Hiru Corp.’s freight and warehouse services across North America underscores its comprehensive approach to supporting and enhancing its mining operations.

Exploration Projects:

Hiru Corp.’s (OTC:HIRU) steadfast dedication to exploration is evident through its ongoing projects in Austria, Australia, and Arizona. These initiatives showcase the company’s approach to uncovering valuable resources and maximizing their potential.

In Arizona, the New Pride Copper Project emerges as a cornerstone endeavor. Situated in a prolific mining district, this project boasts impressive assay results, indicating substantial copper and gold values. The consolidation of land positions underscores Hiru Corp.’s dedication to optimizing resource extraction and maximizing returns for stakeholders.

Meanwhile, in Australia, the Khartoum Project in North Queensland stands out for its significant tin and tungsten mineralization. Extensive drilling programs have revealed broad zones of mineralization, including high-grade base metals, further emphasizing Hiru Corp.’s commitment to value-driven exploration initiatives and potential economic viability.

In Austria, the company’s flagship Austrian Lithium Project represents a pivotal endeavor in the lithium sector. With high-grade lithium assays validating its potential, this project holds promise for meeting the growing demand for lithium-driven technologies. Hiru Corp’s acquisitions and drilling programs underscore its dedication to unlocking value and driving innovation in the lithium market

With a robust leadership team and a diverse portfolio of projects spanning continents, Hiru Corp. (OTC: HIRU) is poised to capitalize on emerging opportunities, potentially driving value for its investors while contributing to the advancement of the global mining industry.

Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Awareness Consulting to assist in the production and distribution of content related to HIRU. ‘CGR’ is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: Capital Gains Report
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: FLORIDA
Country: United States
Website: https://capitalgainsreport.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hiru Corp. (OTC: HIRU): Forging a Path in Metal Mining Exploration

Midlothian Power Washing Explains the Impact of Power Washing on Asphalt Paving

Midlothian Power Washing is a top-rated paving company. In a recent update, the company explained the impact of power washing on asphalt paving.

Midlothian, VA – In a website post, Midlothian Power Washing explained the impact of power washing on asphalt paving.

The paving contractor Midlothian affirmed that one of the significant impacts of power washing on asphalt paving is its ability to improve the surface’s appearance. Asphalt surfaces are highly susceptible to dirt, stains, and oil buildup, which can make them look unsightly. These substances detract from the surface’s aesthetic appeal and pose a safety hazard. Power washing uses high-pressure water to remove deep-seated dirt and stains.

The asphalt contractor Midlothian asserted that another essential impact of power washing on asphalt paving is its role in maintaining the surface’s structural integrity. Over time, dirt, grime, and other substances can build up on the surface and seep into the pavement, causing damage. This can cause cracks, potholes, and other forms of deterioration, which can be costly to repair. By regularly power washing the surface, these harmful substances are removed, preventing them from causing structural damage.

Lastly, the technicians said that power washing plays a crucial role in promoting safety on asphalt paving Midlothian. Oil buildup and other substances can make the surface oily and slippery, posing a significant threat to pedestrians and drivers. Power washing eliminates these hazards, making the surface safer for everyone. This is especially important for high-traffic areas such as parking lots and driveways.

About Midlothian Power Washing

Midlothian Power Washing is a leading paving company. The team specializes in all types of paving services, including residential and commercial projects. From driveways to parking lots, they have the expertise to handle all kinds of paving jobs, big or small. What sets the firm apart from others is its state-of-the-art equipment and technology, as it continuously invests in the latest equipment and techniques to ensure that its customers receive the best results.

Midlothian Power Washing

207 Wylderose Ct, #3 Midlothian, VA 23113, USA

(804) 587-8344

Media Contact
Company Name: Midlothian Power Washing
Contact Person: Terry Sawyer
Email: Send Email
Phone: (804) 587-8344
City: Midlothian
State: Virginia
Country: United States
Website: https://midlothianpowerwashing.com/power-washing-company-in-midlothian/

Hollyland to Preview New Video Production Solutions at NAB 2024

Innovator returns to key industry event with impressive line up of products

Shenzhen, China – April 10^th, 2024 – Hollyland Technology will attend the Las Vegas NAB show, to show and preview the company’s new and existing products for wireless audio and video. NAB 2024 will be held from April 13–17, 2024, at the Las Vegas Convention Center in Las Vegas, Nevada, US. Hollyland is in the Central Hall, at booth C6710.

Hollyland’s newest products highlight the company’s wireless capabilities from video solutions to intercom systems. In addition, Hollyland will soon be releasing a new, improved live streaming camera, updated from the VenusLiv.

Pyro video transmission and upcoming intercom preview

Hollyland will also release the Pyro series, a new wireless video transmission system, this spring. The Pyro series brings innovative multi-person mobile wireless image transmission and monitoring to small or medium commercial and filmmaking teams.

With one transmitter and four receivers, the lightweight Pyro system makes transmission and monitoring more flexible, stable and professional. Pyro has automatic dual-band frequency hopping technology that enables signal transmission at both 2.4 GHz and 5 GHz. The intelligent auto frequency hopping also provides enhanced anti-interference capabilities while reducing lag and improving range. Pyro H has HDMI input/output, while Pyro S has both HDMI and SDI input/output.

The Pyro series provides 4k/30fps transmission capabilities, delivering superior clarity, detail, and realism, making it ideal for professional applications, such as filmmaking.

Hollyland will launch new intercom systems this year. They are perfect for mid and high-end production teams, have seamless roaming capability, and are expandable for larger teams. Compared to competitors’ products, Hollyland’s intercom systems are easier to set up and come with lighter and more comfortable headsets.

Wireless shooting and live-streaming solutions

The Hollyland Wireless Solution Pack provides production teams with the necessary filming assistance for video transmitters and audio to intercom systems – making film production easier and more convenient. This package is designed for Hollyland’s Solidcom C1 Pro, Mars 4K, Cosmo C1, and Mars M1 Enhanced; Hollyland’s entire Lark Series.

In addition, Hollyland will offer camera and wireless microphone solutions that are ideal for live streaming. With the media industry moving towards shorter film content on social media platforms like TikTok, Instagram, and Facebook, live streaming is increasingly popular with content creators. With this in mind, Hollyland has released the live streaming VenusLiv camera, which achieves high-quality live presentation across all platforms. Hollyland’s goal is for entry-level users to be able to create high-quality live streaming using VenusLiv, and other cameras to come in future.

Meet Hollyland at NAB

Hollyland encourages friends, partners, customers – and everyone with an interest in video, audio, wireless and streaming – to visit the Hollyland booth at NAB for coffee, demonstrations, and inside information on the hottest new products. At around 1:00 pm each day there will be a brand presentation and giveaway event. And every day, Justin Porter, the award-winning wedding filmmaker, will give a presentation with tips, lessons from experience, and practical explanations. Justin’s presentation will take place at 4pm on April 15; 11am and 4pm on April 16; and 11am on April 17. There will be giveaways during this event as well.

Hollyland is looking forward to meeting everyone at the Hollyland booth at the Convention Center in Las Vegas.

NAB Details

NAB 2024 (National Association of Broadcasters)

Date: April 13 to 17, 2024

Location: Las Vegas Convention Center, Las Vegas, Nevada, US

Hollyland is in the Central Hall, at Booth C6710

About Hollyland Technology

Shenzhen Hollyland Technology Co., Ltd. (Hollyland) has been empowering global customers with professional solutions for wireless data, audio and video transmission, and wireless intercom since 2013. Hollyland serves many markets, including film-making, television shooting, video production, broadcast, live events, exhibitions, broadcast media, production, theaters, houses of worship, and rental houses.

Visit https://www.hollyland.com/, Hollyland Facebook, Hollyland Instagram.

Media Contact
Company Name: Shenzhen Hollyland Technology Co., Ltd.
Contact Person: Mei Chang
Email: Send Email
Phone: +86 755 266 19163
City: Shenzhen
Country: China
Website: https://www.hollyland.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hollyland to Preview New Video Production Solutions at NAB 2024